E. C. Shamblen

Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin

K. Lasseter, J. Lettieri, R. W. Frost, 1992, Antimicrobial Agents and Chemotherapy.

Steady‐State Pharmacokinetics of Nitrendipine in Hepatic Insufficiency

K. Lasseter, S. Vanov, R. Taylor, 1984, Journal of cardiovascular pharmacology.

Effect of Hydrochlorothiazide on the Pharmacokinetics and Pharmacodynamics of the Angiotensin II Blocker Irbesartan

K. Lasseter, N. Ford, R. Raymond, 1997 .

Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin

A. Mazzu, K. Lasseter, J. Lettieri, 2000, Clinical pharmacology and therapeutics.

Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

B. Gertz, M. Constanzer, A. van Hecken, 1996, The Journal of clinical endocrinology and metabolism.

Comparative absorption of atropine from a metered-dose inhaler and an intramuscular injection.

N. C. Miller, D. Kvam, K. Lasseter, 1992, Therapeutic Drug Monitoring.

The effect of cirrhosis on the steady‐state pharmacokinetics of oral ciprofloxacin

K. Lasseter, J. Lettieri, G. Krol, 1989, Clinical pharmacology and therapeutics.